NO954329L - Forbedrede farmasöytisk akseptable blandinger inneholdende en alkohol og et hydrofobt legemiddel - Google Patents

Forbedrede farmasöytisk akseptable blandinger inneholdende en alkohol og et hydrofobt legemiddel

Info

Publication number
NO954329L
NO954329L NO954329A NO954329A NO954329L NO 954329 L NO954329 L NO 954329L NO 954329 A NO954329 A NO 954329A NO 954329 A NO954329 A NO 954329A NO 954329 L NO954329 L NO 954329L
Authority
NO
Norway
Prior art keywords
alcohol
hydrophobic drug
pharmaceutically acceptable
compositions containing
acceptable compositions
Prior art date
Application number
NO954329A
Other languages
English (en)
Norwegian (no)
Other versions
NO954329D0 (no
Inventor
Bernard Charles Sherman
Original Assignee
Bernard Charles Sherman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bernard Charles Sherman filed Critical Bernard Charles Sherman
Publication of NO954329D0 publication Critical patent/NO954329D0/no
Publication of NO954329L publication Critical patent/NO954329L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO954329A 1993-04-28 1995-10-27 Forbedrede farmasöytisk akseptable blandinger inneholdende en alkohol og et hydrofobt legemiddel NO954329L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ247516A NZ247516A (en) 1993-04-28 1993-04-28 Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
PCT/CA1994/000222 WO1994025068A1 (en) 1993-04-28 1994-04-22 Improved pharmaceutical acceptable compositions containing an alcohol and a hydrophobic drug

Publications (2)

Publication Number Publication Date
NO954329D0 NO954329D0 (no) 1995-10-27
NO954329L true NO954329L (no) 1995-12-21

Family

ID=19924336

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954329A NO954329L (no) 1993-04-28 1995-10-27 Forbedrede farmasöytisk akseptable blandinger inneholdende en alkohol og et hydrofobt legemiddel

Country Status (19)

Country Link
US (1) US5843891A (de)
EP (1) EP0696920B1 (de)
JP (1) JPH08509475A (de)
CN (1) CN1124457A (de)
AT (1) ATE173635T1 (de)
AU (1) AU677660B2 (de)
BR (1) BR9406513A (de)
CA (1) CA2160880A1 (de)
CZ (1) CZ276995A3 (de)
DE (1) DE69414840T2 (de)
FI (1) FI955091A7 (de)
HU (1) HUT73664A (de)
IL (1) IL109401A0 (de)
MX (1) MX9402922A (de)
NO (1) NO954329L (de)
NZ (1) NZ247516A (de)
PL (1) PL311294A1 (de)
WO (1) WO1994025068A1 (de)
ZA (1) ZA942803B (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858401A (en) * 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
HU228855B1 (en) * 1997-03-12 2013-06-28 Abbott Lab Hydrophilic binary systems for the administration of cyclosporine
NZ314702A (en) * 1997-04-29 1998-07-28 Bernard Charles Sherman Pharmaceutical composition comprising a cyclosporin in a solvent system of acetylated monoglycerides and a surfactant and optionally a hydrophilic solvent
US6258783B1 (en) 1997-04-29 2001-07-10 Bernard Charles Sherman Emulsion preconcentrate comprising a cyclosporin and acetylated monoglyceride
FR2764509A1 (fr) * 1997-06-11 1998-12-18 Debiopharm Sa Compositions pharmaceutiques contenant du dichlorhydrate de cinchonine
US6284268B1 (en) 1997-12-10 2001-09-04 Cyclosporine Therapeutics Limited Pharmaceutical compositions containing an omega-3 fatty acid oil
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
EP1418945A2 (de) * 2001-03-13 2004-05-19 Angiotech Pharmaceuticals, Inc. Mizellare arzneimittelabgabe vehikel und ihre anwendungen
US20030157170A1 (en) * 2001-03-13 2003-08-21 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
JP2004532847A (ja) * 2001-04-20 2004-10-28 ザ ユニヴァーシティ オヴ ブリティッシュ コロンビア 疎水性薬物のためのミセル薬物送達システム
US6592899B2 (en) 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
EP1435910B9 (de) * 2001-10-19 2010-02-03 Isotechnika Inc. Neue cyclosporin-analoge mikroemulsionsvorkonzentrate
US20050129718A1 (en) * 2001-12-20 2005-06-16 Sherman Bernard C. Pharmaceutical compositions comprising a cyclosporin, a hydrophilic surfactant and a lipophilic surfactant
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
WO2005053727A2 (en) * 2003-11-29 2005-06-16 Sangstat Medical Corporation Pharmaceutical compositions for bioactive peptide agents
US7135455B2 (en) * 2004-11-15 2006-11-14 Allergan, Inc Methods for the therapeutic use of cyclosporine components
US7151085B2 (en) 2004-11-15 2006-12-19 Allergan, Inc. Therapeutic methods using cyclosporine components
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US20080233053A1 (en) * 2005-02-07 2008-09-25 Pharmalight Inc. Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
EP2020990B1 (de) 2006-05-30 2010-09-22 Intarcia Therapeutics, Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
TWI394564B (zh) * 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
EP2157967B1 (de) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspensionsformulierungen insulinotroper peptide und ihre verwendung
EP2200613B1 (de) 2007-09-21 2018-09-05 The Johns Hopkins University Phenazin-derivate und ihre verwendungen
JP5668476B2 (ja) 2007-10-08 2015-02-12 オーリニア・ファーマシューティカルズ・インコーポレイテッドＡｕｒｉｎｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． カルシニューリン阻害剤またはｍＴＯＲ阻害剤を含む眼科用組成物
EP2240155B1 (de) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US8906414B1 (en) 2009-04-27 2014-12-09 University Of South Florida Methods and compositions for improving bioavailability of epigallocatechin gallate (EGCG)
EP2440185B1 (de) 2009-06-09 2015-04-08 Aurinia Pharmaceuticals Inc. Topische arzneimittelabgabesysteme zur ophthalmischen verwendung
EP3323423B1 (de) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Schnelle initiierung und/oder beendigung der verabreichung substantiell stabiler arzneimittel
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
KR101211902B1 (ko) 2012-04-30 2012-12-13 주식회사 휴온스 사이클로스포린 함유 무자극성 나노에멀젼 안약 조성물
PL2887923T3 (pl) 2012-08-24 2023-08-14 Sun Pharmaceutical Industries Limited Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016044813A1 (en) 2014-09-18 2016-03-24 Virun, Inc. Pre-spray emulsions and powders containing non-polar compounds
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
WO2016205423A2 (en) 2015-06-15 2016-12-22 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
DK3373976T3 (da) 2015-11-10 2024-04-02 Sun Pharmaceutical Ind Ltd Topiske formuleringer og anvendelser deraf
NZ785158A (en) 2016-02-29 2025-03-28 Sun Pharmaceutical Ind Ltd Topical cyclosporine-containing formulations and uses thereof
KR20240037175A (ko) 2016-05-16 2024-03-21 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
EP3824296B1 (de) 2018-07-20 2026-04-01 Lipocine Inc. Orale pharmazeutische zusammensetzung mit testosterontridecanoat und/oder testosterondodecanoat zur behandlung von lebererkrankungen
JP2026027576A (ja) * 2022-11-22 2026-02-19 一丸ファルコス株式会社 Ｒａｓ阻害ペプチドを含む組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS498246B1 (de) * 1965-07-15 1974-02-25
JPS5919525B2 (ja) * 1976-09-03 1984-05-07 武田薬品工業株式会社 注射剤
FI65914C (fi) * 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
JPS6226220A (ja) * 1985-07-29 1987-02-04 Hishiyama Seiyaku Kk ケトプロフエン注射液
JP2577049B2 (ja) * 1987-06-04 1997-01-29 三共株式会社 シクロスポリン製剤
CH679119A5 (de) * 1988-05-13 1991-12-31 Sandoz Ag
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
HU208491B (en) * 1990-11-27 1993-11-29 Gyogyszerkutato Intezet Process for producing oral pharmaceutical composition containing cyclosporin
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
JPH0558906A (ja) * 1991-09-06 1993-03-09 Sankyo Co Ltd シクロスポリン点眼製剤

Also Published As

Publication number Publication date
ZA942803B (en) 1996-01-22
JPH08509475A (ja) 1996-10-08
CA2160880A1 (en) 1994-11-10
AU677660B2 (en) 1997-05-01
FI955091L (fi) 1995-12-14
DE69414840T2 (de) 1999-04-22
MX9402922A (es) 1997-05-31
NO954329D0 (no) 1995-10-27
US5843891A (en) 1998-12-01
BR9406513A (pt) 1996-01-09
CZ276995A3 (en) 1996-03-13
FI955091A7 (fi) 1995-12-14
CN1124457A (zh) 1996-06-12
PL311294A1 (en) 1996-02-05
WO1994025068A1 (en) 1994-11-10
NZ247516A (en) 1995-02-24
EP0696920A1 (de) 1996-02-21
IL109401A0 (en) 1994-11-28
AU6673494A (en) 1994-11-21
EP0696920B1 (de) 1998-11-25
HU9503075D0 (en) 1995-12-28
ATE173635T1 (de) 1998-12-15
HUT73664A (en) 1996-09-30
FI955091A0 (fi) 1995-10-25
DE69414840D1 (de) 1999-01-07

Similar Documents

Publication Publication Date Title
NO954329D0 (no) Forbedrede farmasöytisk akseptable blandinger inneholdende en alkohol og et hydrofobt legemiddel
BR9507640A (pt) Processo para estabilizar derivados de duocarmicida e composição farmacêutica
KR950007841A (ko) 트라마돌 염을 함유하는 서방성 약물 제제
NO952269L (no) Stabiliserte medisinske aerosollösnings-formuleringer
KR940005270A (ko) 뼈 손실 예방에 유용한 벤조티오펜
DK1073439T3 (da) Farmaceutisk sammensætning
CA2081068A1 (en) Antiviral 4-substituted-2-deoxy-2,3-didehydro-derivatives of .alpha.-d-neuraminic acid
BR9509019B1 (pt) comprimido isento de solventes orgÂnicos.
ATE131730T1 (de) Nukleosidanalogen enthaltende antiviren- zubereitungen
YU46012B (sh) Postupak za izradu vodenih gelirajućih rastvora derivata arilpropionske kiseline koji mogu da se resporbuju kroz kožu
DK0497816T3 (da) Behandling af HIV-infektioner og forbindelser anvendelige derved
DE59202280D1 (de) Antiphlogistisches Mittel.
PA8542701A1 (es) Composición parenteral reconstituible
EP0734387A4 (de) Hiv-proteaseinhibitoren
PT96381A (pt) Processo para a preparacao de derivados de 2-aminopirimidina-4-carboxamida e de composicoes farmaceuticas que os contem
ES2173883T3 (es) Utilizacion de derivados de piperacina-acetamida contra los daños de reperfusion.
AU4419497A (en) Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
CS261206B2 (en) Isotonization and stabilization agent
ES2310550T3 (es) Preparacion liquida acuosa de pranoprofeno.
NO20063208L (no) UV-stabil, flytende eller halvfast transdermal administrasjonsform omfattende en lysomfintlig aktiv ingrediens
KR930004460A (ko) 에이(a) 87689 화합물
NO961061L (no) Terapeutisk aktive antracyclin-disakkarider
LEE et al. Visual and Refractive Results After Excimer Laser Photorefractive Keratectomy: Six Months Follow up
IT1251484B (it) Composizione per la protezione di scritte in inchiostro contro la cancellazione
KR950005303A (ko) 진균 감염 치료 방법(method of treating fungal infections)